Clinical Trials Browser

OTHER × AVB-500 fusion protein × Gynecologic × Clear all

NCT04019288 2025-06-11

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05826015 2024-10-02

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Phase 1 Withdrawn

Recurrent High Grade Uterine Cancer